Strong Quarter for Merck KGaA - Analyst Blog
March 08 2013 - 3:40AM
Zacks
Merck KGaA (MKGAF)
reported fourth quarter 2012 earnings per American Depository
Receipt (ADR) of $2.66, up 18.8% year over year.
Revenues for the reported quarter were up 8% year over year with
currency movement boosting revenues by 1.8%.
Full year 2012 earnings per share
were $9.78, up 3.5%. Revenues in 2012 increased 8.7%.
Segment Sales in
Detail
The company operates under four
divisions: Merck Serono, Consumer Health Care, Merck Millipore and
Performance Materials.
Merck Serono’s revenues increased 7.8% in 2012, driven by strong
performance in North America and the emerging markets. Due to price
increases in the US, Rebif sales grew organically by 7.5% in 2012.
Erbitux sales grew organically by 1.9% in 2012.
The Consumer Health Care division’s revenues decreased 4.3% in
2012, primarily due to lower sales in Europe, its largest
market.
The Merck Millipore division’s revenues went up 9% in 2012. Growth
was driven by positive exchange rate effects and acquisitions in
the areas of cell culture media, cell imaging and microbial
testing.
The Performance Materials division’s revenues jumped 14.3% in 2012
due to strong demand for liquid crystals materials.
In 2012, research and development (R&D) expenses were €1.5
billion, down 0.2%. In 2012, administration expenses were €552.2
million, up 3.1% and selling and marketing expenses were €2.4
billion, up 1.1%.
Outlook
For 2013 and 2014, Merck KGaA expects revenues to grow organically
at a moderate pace.
While the company expects Rebif sales to remain stable, an
additional competitior is expected to enter the market by the end
of March. As a result, Rebif is expected to show growth in the
first two quarters of 2013 and contract in the second half of the
year. Meanwhile, Erbitux is expected to remain stable or increase
slightly.
Merck KGaA carries a Zacks Rank #3
(Hold). Currently, companies like Lannett Company,
Inc. (LCI), SIGA Technologies, Inc.
(SIGA) and QLT Inc. (QLTI) look more attractive
with a Zacks Rank #1 (Strong Buy).
LANNETT INC (LCI): Free Stock Analysis Report
MERCK KGAA (MKGAF): Get Free Report
QLT INC (QLTI): Free Stock Analysis Report
SIGA TECH INC (SIGA): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Merck KGAA (PK) (USOTC:MKGAF)
Historical Stock Chart
From Oct 2024 to Nov 2024
Merck KGAA (PK) (USOTC:MKGAF)
Historical Stock Chart
From Nov 2023 to Nov 2024